Serena Williams' suggestion that injectable weight loss drugs could have helped her in tennis is part of an ongoing ...

GLP-1s aren't FDA-approved to treat rheumatoid arthritis, but many people notice improvement in their inflammation with the ...

The retired tennis pro explained that she’s trying to combat the stigma associated with weight loss drugs after losing 31 ...

GLP-1 drugs were also associated with a slight increase in risk for kidney cancer. The increase was not statistically ...

Telehealth company Ro has a new spokesperson for its booming GLP-1 business: Serena Williams, the 23-time Grand Slam champion ...

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

A study has found that adults with obesity taking GLP-1 receptor agonists may face significantly lower risk of developing certain cancers. The cohort study was led by researchers from the Indiana ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Sara H. Jodka of Dickinson Wright PLLC discusses the legal landscape surrounding GLP-1 programs for weight loss, in light of ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...